The European Commission has approved the pending takeover of Catalent by Novo Holdings without conditions.
The transaction is expected to close towards the end of the year if conditions are met. Catalent chief executive Alessandro Maselli said on Friday the approval was an important milestone in completing the sale. Novo Holdings, which owns a majority stake in Wegovy maker Novo Nordisk, agreed in February to buy Catalent for $16.5 billion including debt.
In return, Novo Holdings will sell three of Catalent’s key assets to Novo Nordisk for $11 billion to help the drugmaker ramp up production of its top-selling diabetes and obesity drugs.
By Connor Hart
DOW JONES
Selected leverage products on Catalent
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Catalent
The leverage must be between 2 and 20
Advertising